Contact

Please use this form to send email to PR contact of this press release:
StarMab BioMed’s First-in-Class, Dual-Target Anti-Tumor Drug SM2275 for Novel Immunotherapy Receives FDA IND Approval

TO:
W T Mason
Sage Healthcare
+44 7785 950134

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.
	SEND EMAIL